ART Advanced Research Technologies Inc.

ART Advanced Research Technologies Inc.

March 29, 2007 13:50 ET

ART: Papers Published in Applied Optics Peer-Reviewed Journal Report on Optimization of Fluorescence Imaging Data using eXplore Optix

MONTREAL, CANADA--(CCNMatthews - March 29, 2007) - ART Advanced Research Technologies Inc. ("ART")(TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, is pleased to announce that Applied Optics, a peer-reviewed, widely distributed publication of the Optical Society of America, has published two articles by ART research teams working on the optimization of the eXplore Optix™ device, in the April 1, 2007 issue.

In the article entitled "Sensitivity characterization of a time-domain fluorescence imager: eXplore Optix", a methodology is described that characterizes the sensitivity of fluorescence imaging devices by taking into account the effect of the background signal.

In the second article, entitled "Comparison of simplified Monte Carlo simulation and diffusion approximation for the fluorescence signal from phantoms with typical mouse tissue optical properties", the authors computed fluorescent signals from mouse-tissue-like phantoms using both the Monte Carlo simulation and the diffusion approximation. The relative difference in signal intensity between the two methods was found to be less than 30%, suggesting that the diffusion approximation is a valid approach in mouse tissue.

This Applied Optics feature issue on Topics in Biomedical Optics highlights papers presented at the 2006 Biomedical Optics Topical Meeting sponsored by the Optical Society of America. The feature includes 40 papers that represent a cross section of topics that were covered at the meeting.

The print issue of Applied Optics including these articles will be available on April 1st, 2007. An electronic version of the articles is already accessible online, and can be found at .

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. eXplore Optix™, an optical molecular imaging device designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is distributed by GE Healthcare and is used by industry and academic leaders worldwide. SoftScan®, an optical medical imaging device, is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra™ line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at .

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the Management Proxy Circular of ART dated October 24, 2006, available on SEDAR ( under the profile of "ART Advanced Research Technologies Inc. (old)" (ART's predecessor issuer).

Contact Information

  • ART Advanced Research Technologies Inc.
    Jacques Bedard
    Chief Financial Officer
    ART Advanced Research Technologies Inc.
    Mario Khayat
    Vice President, Optical Products